S Nayak1, S L Greenspan2. 1. Berkeley Madonna, Inc., 1135 Spruce St., Berkeley, CA, 94707-2629, USA. smita.nayak@berkeleymadonna.com. 2. University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Abstract
We performed a systematic review on the effect of drug holidays (discontinuation) on bone mineral density (BMD) and fracture risk. Bisphosphonate discontinuation may be considered for women who do not have low hip BMD after 3-5 years of initial treatment, while women who have low hip BMD may benefit from treatment continuation. INTRODUCTION: We performed a systematic review and meta-analysis on the effect of drug holidays (discontinuation) on BMD and fracture risk. METHODS: We searched PubMed, Embase, and Cochrane Library databases to locate controlled clinical trials and cohort studies evaluating the effect of drug holidays/discontinuation versus osteoporosis treatment continuation. We performed random-effects meta-analyses of hazard ratios of hip and any clinical osteoporotic fracture for individuals who discontinued bisphosphonates compared to persistent users. RESULTS: Thirteen records reporting results from eight different studies met inclusion criteria. The FLEX study found a reduced clinical vertebral fracture risk with 10 years of alendronate therapy compared to 5 (RR 0.45, 95% CI 0.24-0.85), and the HORIZON extension studies found a reduced risk of morphometric vertebral fracture with 6 years of zoledronic acid therapy compared to 3 (OR = 0.51, 95% CI 0.26-0.95); subgroup analyses showed that women with low hip BMD T-scores after the initial treatment period benefitted from continued treatment in terms of reduced vertebral fracture risk. Meta-analysis of adjusted hazard ratios of hip and any clinical osteoporotic fracture for women who discontinued bisphosphonates revealed no significant differences in the risk of hip fracture (summary estimate of HR 1.09, 95% CI 0.87-1.37) or any clinical fracture (summary estimate of HR 1.13, 95% CI 0.75-1.70) compared to persistent users. CONCLUSIONS: Bisphosphonate discontinuation may be considered for women who do not have low hip BMD after 3 to 5 years of initial treatment, while women who have low hip BMD may benefit from treatment continuation.
We performed a systematic review on the effect of drug holidays (discontinuation) on bone mineral density (BMD) and fracture risk. Bisphosphonate discontinuation may be considered for women who do not have low hip BMD after 3-5 years of initial treatment, while women who have low hip BMD may benefit from treatment continuation. INTRODUCTION: We performed a systematic review and meta-analysis on the effect of drug holidays (discontinuation) on BMD and fracture risk. METHODS: We searched PubMed, Embase, and Cochrane Library databases to locate controlled clinical trials and cohort studies evaluating the effect of drug holidays/discontinuation versus osteoporosis treatment continuation. We performed random-effects meta-analyses of hazard ratios of hip and any clinical osteoporotic fracture for individuals who discontinued bisphosphonates compared to persistent users. RESULTS: Thirteen records reporting results from eight different studies met inclusion criteria. The FLEX study found a reduced clinical vertebral fracture risk with 10 years of alendronate therapy compared to 5 (RR 0.45, 95% CI 0.24-0.85), and the HORIZON extension studies found a reduced risk of morphometric vertebral fracture with 6 years of zoledronic acid therapy compared to 3 (OR = 0.51, 95% CI 0.26-0.95); subgroup analyses showed that women with low hip BMD T-scores after the initial treatment period benefitted from continued treatment in terms of reduced vertebral fracture risk. Meta-analysis of adjusted hazard ratios of hip and any clinical osteoporotic fracture for women who discontinued bisphosphonates revealed no significant differences in the risk of hip fracture (summary estimate of HR 1.09, 95% CI 0.87-1.37) or any clinical fracture (summary estimate of HR 1.13, 95% CI 0.75-1.70) compared to persistent users. CONCLUSIONS:Bisphosphonate discontinuation may be considered for women who do not have low hip BMD after 3 to 5 years of initial treatment, while women who have low hip BMD may benefit from treatment continuation.
Entities:
Keywords:
Bisphosphonates; Drug holiday; Meta-analysis; Osteoporosis; Systematic review
Authors: R P Tonino; P J Meunier; R Emkey; J A Rodriguez-Portales; C J Menkes; R D Wasnich; H G Bone; A C Santora; M Wu; R Desai; P D Ross Journal: J Clin Endocrinol Metab Date: 2000-09 Impact factor: 5.958
Authors: Dennis M Black; Ann V Schwartz; Kristine E Ensrud; Jane A Cauley; Silvina Levis; Sara A Quandt; Suzanne Satterfield; Robert B Wallace; Douglas C Bauer; Lisa Palermo; Lois E Wehren; Antonio Lombardi; Arthur C Santora; Steven R Cummings Journal: JAMA Date: 2006-12-27 Impact factor: 56.272
Authors: Ann V Schwartz; Douglas C Bauer; Steven R Cummings; Jane A Cauley; Kristine E Ensrud; Lisa Palermo; Robert B Wallace; Marc C Hochberg; Adrianne C Feldstein; Antonio Lombardi; Dennis M Black Journal: J Bone Miner Res Date: 2010-05 Impact factor: 6.741
Authors: Nguyen D Nguyen; Henrik G Ahlborg; Jacqueline R Center; John A Eisman; Tuan V Nguyen Journal: J Bone Miner Res Date: 2007-06 Impact factor: 6.741
Authors: Kristine E Ensrud; Elizabeth L Barrett-Connor; Ann Schwartz; Arthur C Santora; Douglas C Bauer; Shailaja Suryawanshi; Adrianne Feldstein; William L Haskell; Marc C Hochberg; James C Torner; Antonio Lombardi; Dennis M Black Journal: J Bone Miner Res Date: 2004-03-29 Impact factor: 6.741
Authors: Henry G Bone; David Hosking; Jean-Pierre Devogelaer; Joseph R Tucci; Ronald D Emkey; Richard P Tonino; Jose Adolfo Rodriguez-Portales; Robert W Downs; Jayanti Gupta; Arthur C Santora; Uri A Liberman Journal: N Engl J Med Date: 2004-03-18 Impact factor: 91.245
Authors: Celia L Gregson; David J Armstrong; Jean Bowden; Cyrus Cooper; John Edwards; Neil J L Gittoes; Nicholas Harvey; John Kanis; Sarah Leyland; Rebecca Low; Eugene McCloskey; Katie Moss; Jane Parker; Zoe Paskins; Kenneth Poole; David M Reid; Mike Stone; Julia Thomson; Nic Vine; Juliet Compston Journal: Arch Osteoporos Date: 2022-04-05 Impact factor: 2.879
Authors: Panagiotis Anagnostis; Stavroula A Paschou; Eustathios Kenanidis; Irene Lambrinoudaki; Michael Potoupnis; Eleftherios Tsiridis; Dimitrios G Goulis Journal: Case Rep Womens Health Date: 2019-06-08